Australian effective per-patient price under "Netflix" model for HepC treatment ~US$7350 or 1/7th the price it probably would have gotten otherwise -- enables universal access. Largest actual use of #delinkage: pay for innovation without high prices
"Netflix" drug pricing: Australia paid a lump sum of $1bill to treat unlimited # of HepC patients over 5 yrs. Estimated to pay $9.5k per patient compared to $73k in the US. Payers/suppliers have predictable costs/revenue + patients get access. win-win-win
Australia implementation of 'lump-sum' payment for HCV treatment, analogous to "Netflix" model. From . Program treating many more than anticipated, per Rx price $7,300, govt saving: $5B. cc
This is amazing. Australia spent $766million US dollars to treat unlimited number of Hep C patients over 5 years In 2015, Medicare ALONE spent ~$7BILLION (minus rebates) on Harvoni to treat 76,000 patients.
Louisiana is proud to have led the national charge on a subscription model with the goal of eliminating Hepatitis C. Glad to see the results from Australia and hopeful for their application for the people of my state. ⁦⁦
⁩ ⁦⁩ proud to be leading the nation on the subscription model- We have made the elimination of Hep C a top priority since the beginning of the administration and think this voluntary agreement holds great promise.
Australia's 5 yr DAA program lauded in . Per patient cost estimate of US $7,352. A win for people with #HCV, Government, and Australian community. Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to Hepatitis C | NEJM
Here's an idea for and ... India should STOP paying for TB drug courses, for TB & DRTB, and put out a multi year bid for a fixed cost for all the drugs it needs. Reduce costs of treatment by 50% for DS & 80% for DRTB. Bonkers?
Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to Hepatitis C | NEJM
"The arrangement is arguably the largest real-world implementation of “delinkage,” in which pharmaceutical innovation is rewarded separately from drug prices, a principle that has been widely endorsed as a way to support both innovation and access."
"The cost of treating each additional patient is zero to marginal"> Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to #Hepatitis C | NEJM #HCV #DAAs